Cargando...
MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G(D2) immunotherapy
High-risk neuroblastoma (HR-NB) includes MYCN-amplified stage 2/3, but reports covering anti-G(D2) immunotherapy, which recently became standard for HR-NB, do not provide details on this subset. We now report on all 20 MYCN-amplified stage 2/3 patients who received induction chemotherapy at our cent...
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5707022/ https://ncbi.nlm.nih.gov/pubmed/29221128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20513 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|